BioStar Capital is a value-add investment firm focused on transformational medical device technologies in cardiovascular and orthopaedic medicine. Combining the insight of experienced investment professionals and world-renowned medical thought leaders, BioStar Capital identifies proprietary technologies that serve unmet patient needs and fit the acquisition criteria of leading medical device companies. BioStar Capital fills an important gap in medical device innovation and provides operational skills and clinical expertise in addition to capital, enabling the firm to actively mitigate risk, optimize product development, and secure successful exit. The firm has invested in over 30 med-tech companies, many of which have been acquired by a major medical device manufacturer.

BioStar News
Portfolio News

January 15, 2021

DeviceTalks Weekly features Mark Toland, BioStar Entrepreneur-in-Residence: Digging into the Digital Medtech & Surgical Worlds

>> Read More

September 15, 2020

Mark Toland, Former CEO of Siemens-Owned Corindus, Joins BioStar Capital as Partner and Entrepreneur in Residence

>> Read More

April 6, 2021

TransMedics Announces Positive FDA Advisory Committee Vote for OCS Heart System

>> Read More

April 1, 2021

Trice Medical continues mission of making elective procedures more efficient through the acquisition of Tenex Health

>> Read More

Active Portfolio Companies
ASI Logo - New.png
AVS Logo.png
Foldax Logo (Black).jpg
OO Logo_edited.png
SENS Logo.png
Trice Logo - New.png
BioStar Capital Logo - W.png

BioStar Capital
206 Bridge Street
Charlevoix, MI  49720

TEL 231 497 1286   |   FAX 231 497 1298


© 2015 BioStar Capital